| Name | Title | Contact Details |
|---|
Principia Biopharma is a privately-held biopharmaceutical company focused on the discovery and development of best-in-class small molecule drugs for autoimmune diseases and cancer. The company uses its proprietary technology, licensed from the University of California San Francisco, to enable a new approach to making small molecules that are potent, safe and have antibody-like specificity. Principia raised $40 million in a Series A round of financing from a leading group of healthcare investors, including New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.
We cultivate authentic materials without compromise,by harnessing science and nature responsibly by partnering the most innovative minds in science and technology with the finest craftspeople to accelerate the use of cellular agriculture for good.
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic`s mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient`s journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Our technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic`s goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians with real-time information to guide treatment choices.
The focus of Regen BioPharma, Inc. is to developing translational medicine platforms for the rapid commercialization of stem cell therapies and to advance intellectual property licensed from entities, institutions and universities that show promise towards fulfilling the purpose of increased quality of life. Regen BioPharma has reviewed more than 20,000 US issued patents covering stem cell related subject matter, created a shortlist of 30 promising technologies for rapid commercialization, and currently is in negotiations to license several of these. The Regen BioPharma business model is to take multiple stem cell therapeutics to and through the human "safety and signal of efficacy" stage (Phase I/II clinical trials), followed by exit. Having assembled a core infrastructure specialized in obtaining regulatory approval and executing clinical trials in cell therapy, we aim to act as a "superincubator" that within 1-2 years grows technologies from laboratory to an asset ready for spin-off or sale.
Botanix Pharmaceuticals is a biotechnology company listed on the ASX (ASX: BOT) with headquarters in Perth, Australia, and Philadelphia, USA. The company specializes in clinical-stage dermatology and antimicrobial treatments, focusing on synthetic cannabinoid-based therapies that utilize cannabidiol (CBD) and its proprietary skin-delivery technology, Permetrex™. The companys product pipeline includes several innovative therapies aimed at addressing common dermatological conditions. These include BTX 1503 for moderate-to-severe acne, BTX 1702 for rosacea, and BTX 1204A for moderate atopic dermatitis. Additionally, BTX 1801 targets infections in hemodialysis patients and other antimicrobial applications. All products leverage the Permetrex™ delivery system to enhance skin absorption, and Botanix is also exploring veterinary applications for atopic dermatitis. Botanix aims to improve patient outcomes by addressing unmet needs in dermatology and antimicrobial resistance, positioning itself as a leader in cannabinoid-based dermatological treatments.